Paratek Pharmaceuticals (TSPT) Receives News Sentiment Score of 0.12

News articles about Paratek Pharmaceuticals (NASDAQ:TSPT) have been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Paratek Pharmaceuticals earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.1531810065834 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

ILLEGAL ACTIVITY WARNING: This article was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://ledgergazette.com/2017/10/10/paratek-pharmaceuticals-tspt-receives-news-sentiment-score-of-0-12.html.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Insider Buying and Selling by Quarter for Paratek Pharmaceuticals (NASDAQ:TSPT)

Receive News & Ratings for Paratek Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply